Generic competition on the horizon as many pharmaceutical companies face patent expirations
The impact of generic drugs-which now account for more than 70% of all prescriptions dispensed in the United States-will continue to increase as some of the world's most-prescribed products lose their patent protection in 2011 and begin facing generic competition.
The impact of generic drugs-which now account for more than 70% of all prescriptions dispensed in the United States-will continue to increase as some of the world’s most-prescribed products lose their patent protection in 2011 and begin facing generic competition.
Among the brand names facing the end of market exclusivity this year are Lipitor (Pfizer), Plavix (Bristol-Myers Squibb/Sanofi Pharmaceuticals), Zyprexa (Eli Lilly), and Levaquin (Ortho-McNeil). Together, these drugs accounted for more than 93 million prescriptions dispensed and generated more than $17 billion in total sales during the past 12 months, according to IMS Health.
The full impact of patients shifting to lower-cost generic alternatives for these products, as well as other brands in their therapy classes, mostly will be felt in 2012, because the timing and expected competitive intensity among generic entrants, IMS noted.
In 2011, generic competition in the United States is expected to dampen sales for about $30 billion worth of drugs facing patent and exclusivity cliffs, according to reports from IMS and Credit Suisse.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
